Sexual Dysfunction — Types, Causes, Diagnosis & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Sexual dysfunction refers to persistent and recurrent problems in any phase of the sexual response cycle — desire, arousal, orgasm, or related pain — that cause personal distress or interpersonal difficulty. The DSM-5 classifies sexual dysfunctions by specific category and specifies whether they are lifelong (primary) or acquired (secondary), generalised or situational, and whether they are caused by psychological, relationship, medical, or substance-related factors. Key categories: in men — erectile dysfunction (ED), premature ejaculation (PE), delayed ejaculation, and male hypoactive sexual desire disorder; in women — female sexual interest and arousal disorder (FSIAD), female orgasmic disorder, genitopelvic pain and penetration disorder (GPPPD — encompasses vaginismus and dyspareunia). Sexual dysfunction is highly prevalent — affecting an estimated 31% of men and 43% of women in population-based studies. In women over 45, nearly 50% report at least one sexual concern. ED affects approximately 30 million men in the USA and rises steeply with age (present in 40% of men at 40 and 70% of men at 70). Significantly, sexual dysfunction is frequently comorbid with depression, anxiety, cardiovascular disease, diabetes, relationship difficulties, and medication side effects — making thorough assessment essential.

Sexual dysfunction results from the complex interaction of biological, psychological, interpersonal, and sociocultural factors — the biopsychosocial model. Organic (physical) causes: cardiovascular disease and atherosclerosis (ED is an early marker of endothelial dysfunction — a penile erection requires intact arterial vasodilation); diabetes mellitus (autonomic neuropathy and vascular disease cause ED in 50-75% of diabetic men; also causes reduced lubrication and arousal in women); hypogonadism (low testosterone reduces desire and erectile function in men; low oestrogen post-menopause causes vaginal dryness, dyspareunia, and reduced desire); pelvic or prostate surgery (radical prostatectomy causes ED in 30-80% from cavernosal nerve injury); medications (SSRIs cause delayed ejaculation and anorgasmia, antihypertensives — especially beta-blockers and thiazides — reduce libido and cause ED, antipsychotics cause hyperprolactinaemia reducing desire); neurological disorders (MS, Parkinson's, spinal cord injury); and chronic illness (chronic pain, cancer, renal failure). Psychological and interpersonal causes: depression and anxiety (most significant psychological causes of sexual dysfunction — SSRIs and SNRIs paradoxically also cause sexual side effects); relationship conflict and poor communication; sexual trauma and PTSD; performance anxiety (especially male ED and PE); body image and self-esteem issues; and cultural or religious attitudes toward sexuality. Genitopelvic pain (GPPPD/vaginismus): pelvic floor hypertonia (hypertonicity causing involuntary spasm), vulvodynia (chronic vulvar pain — often neurological), vestibulodynia, lichen sclerosus, endometriosis, recurrent vulvovaginal infections, childbirth-related trauma, and menopausal genitourinary syndrome (GSM).

Erectile dysfunction (ED): inability to achieve or maintain an erection sufficient for satisfactory sexual activity — present for at least 3 months for clinical diagnosis. Distinguish: psychogenic ED (morning erections preserved, situational ED, sudden onset, younger man with anxiety) from organic ED (gradual onset, absent morning erections, older man with cardiovascular risk factors). Premature ejaculation (PE): ejaculation occurring within approximately 1-2 minutes of vaginal penetration (or before, or shortly after penetration) with inability to delay, causing distress — the most common male sexual dysfunction (affects 20-30% of men). Delayed ejaculation: marked delay in or inability to achieve ejaculation despite adequate stimulation and desire — less common (1-4%); often from SSRIs, neurological conditions, or psychological blocks. Male hypoactive sexual desire disorder (MHSDD): persistently low or absent sexual thoughts, fantasies, or desire — associated with hypogonadism, depression, relationship issues. Female sexual interest and arousal disorder (FSIAD): absent or reduced interest in sexual activity, erotic thoughts, arousal, or sexual excitement and pleasure during activity — requires personal distress. Genitopelvic pain and penetration disorder (GPPPD): difficulty or inability with vaginal penetration; marked vulvovaginal or pelvic pain during vaginal intercourse or penetration attempts; marked fear or anxiety about pain; and marked tightening of pelvic floor muscles during penetration attempts (the successor diagnosis to vaginismus and dyspareunia).

Assessment requires a sensitive, non-judgmental biopsychosocial history: detailed sexual history (nature of the dysfunction, onset, context, partner relationship, sexual orientation, prior sexual function, satisfaction, and distress); medical history (cardiovascular risk factors, neurological conditions, hormonal disorders, prior pelvic or prostate surgery, obstetric history); full medication review; mental health history (depression, anxiety, trauma, PTSD); relationship history and quality; and cultural or religious factors. Validated questionnaires: International Index of Erectile Function (IIEF-5) for ED; Female Sexual Function Index (FSFI) for female dysfunction; Premature Ejaculation Diagnostic Tool (PEDT). Physical examination: BP measurement, BMI, genital examination (phimosis, Peyronie's plaques, testicular size in men; vulvar skin changes — lichen sclerosus, atrophy — cervical excitation, pelvic floor tone in women), cardiovascular system examination. Investigations for organic causes: testosterone (total and free), sex hormone-binding globulin (SHBG), LH, FSH, prolactin, oestradiol; HbA1c and fasting glucose (diabetes); lipid profile; thyroid function; morning testosterone (hypogonadism); in ED — penile Doppler ultrasound (arterial insufficiency vs. venous leak); nocturnal penile tumescence testing (distinguishes psychogenic from organic ED); pelvic floor physiotherapy assessment (GPPPD — identifies hypertonic pelvic floor, pain mapping).

Erectile dysfunction: lifestyle modification first — smoking cessation, weight loss, regular aerobic exercise, alcohol reduction (often significantly improves ED, particularly in younger men); PDE5 inhibitors (phosphodiesterase type 5 inhibitors) are the mainstay of pharmacological treatment. Sildenafil (Viagra) 50-100 mg taken 30-60 minutes before intercourse — most rapid onset (effective within 15-60 minutes); tadalafil (Cialis) 10-20 mg — longest duration (up to 36 hours, also available as 5 mg daily for continual readiness); vardenafil (Levitra) and avanafil (Stendra) — alternatives. All are equally effective (approximately 60-70% improvement in erectile function) but not aphrodisiacs — require sexual stimulation. Contraindicated with nitrates (risk of profound hypotension). Vacuum erection devices, intracavernosal alprostadil injection, and penile implants for refractory ED. Premature ejaculation: behavioural techniques (start-stop technique, squeeze technique — effective when combined with partner cooperation); topical anaesthetics (lidocaine 2.5%/prilocaine 2.5% — EMLA cream or lidocaine spray applied to the glans 10-20 minutes before intercourse); dapoxetine (a short-acting SSRI — 30-60 mg taken 1-3 hours before intercourse — the only FDA/EMA-approved pharmacological treatment for PE); regular SSRIs (daily sertraline, paroxetine, or fluoxetine — useful for daily treatment, not on-demand). Hypogonadism: testosterone replacement therapy (TRT) — gels, patches, or injections — when documented low testosterone (below 12 nmol/L) causing symptoms; monitor prostate (PSA) and haematocrit. Female sexual dysfunction: GSM and dyspareunia (menopause-related): vaginal oestrogen (local — cream, pessary, ring — minimal systemic absorption, safe even in breast cancer survivors when vaginal dryness is severe); systemic MHT (menopausal hormone therapy) for women without contraindication; ospemifene (SERM — oral alternative to vaginal oestrogen for dyspareunia). FSIAD: flibanserin (Addyi) — FDA-approved for premenopausal women with HSDD (taken daily — modest effect, contraindicated with alcohol); bremelanotide (Vyleesi — subcutaneous injection on-demand). Pelvic floor physiotherapy (specialist): first-line for GPPPD/vaginismus — progressive vaginal dilators, internal manual therapy, biofeedback; highly effective. Sex therapy/CBT: essential component of treatment for all sexual dysfunctions — addresses performance anxiety, relationship factors, communication, and psychological contributors.

Relationship breakdown and interpersonal distress (untreated sexual dysfunction causes significant relationship strain and communication breakdown; secondary dysfunction in the partner is common — 40-50% of partners of men with untreated ED develop responsive sexual dysfunction). Depression and anxiety (both cause and result from sexual dysfunction — a self-reinforcing cycle requiring simultaneous treatment of sexual and psychological symptoms). Post-SSRI sexual dysfunction (PSSD — persistent anorgasmia, genital numbness, and loss of libido continuing months to years after SSRI discontinuation; mechanism under investigation). Priapism from PDE5 inhibitors or intracavernosal alprostadil (prolonged painful erection exceeding 4 hours — rare but requires immediate urological emergency treatment to prevent permanent ischaemic erectile damage). Vaginismus complications: avoidance of gynaecological examinations, cervical smear tests, and contraceptive options — leading to delayed cancer screening and unplanned pregnancy.

Cardiovascular risk factor management is simultaneously prevention for erectile dysfunction — smoking cessation, weight management, regular aerobic exercise, blood pressure control, and lipid management reduce both cardiovascular disease and ED risk. Erectile dysfunction is now recognised as a sentinel event for cardiovascular disease — a man with ED and no other cardiovascular symptoms should undergo cardiovascular risk assessment. Avoid medications that cause sexual dysfunction when alternatives exist — discuss sexual side effects with your prescriber before starting antihypertensives, antidepressants, or antipsychotics. Manage depression and anxiety proactively — both directly cause sexual dysfunction, and their treatment with SSRIs frequently introduces further sexual side effects (SSRI sexual side effects can be managed with dose reduction, switching to bupropion or mirtazapine, or adding a PDE5 inhibitor). Maintain open communication with sexual partners — relationship satisfaction and communication quality are among the strongest protective factors for sexual function. Address hormonal changes early — peri-menopausal and post-menopausal women experiencing sexual symptoms should discuss hormone therapy options proactively, before symptoms become entrenched and distressing.

Seek a GP or sexual health specialist consultation for: erectile dysfunction that is persistent (lasting more than 3 months) or significantly distressing — especially in men under 50 where cardiovascular risk assessment is warranted; loss of sexual desire that is distressing to you or affecting your relationship; painful intercourse (dyspareunia or vaginismus) — which is often highly treatable with pelvic floor physiotherapy; premature ejaculation causing significant distress or relationship problems; or any change in sexual function following a new medication, pelvic surgery, or new medical diagnosis. Do not suffer in silence — sexual health is a recognised component of overall health and wellbeing. GPs, urologists, gynaecologists, and specialist sexual medicine physicians are trained to discuss and manage these problems. Psychological assessment is appropriate when depression, anxiety, sexual trauma, or relationship difficulties are contributing — sex therapy is evidence-based and highly effective.